2nd RNA Targeted Drug Discovery SummitAt a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Share X2nd RNA Targeted Drug Discovery Summithttps://pharmaphorum.com/events/2nd-rna-targeted-drug-discovery-summit/
GlycoMimetics craters as Pfizer says rivipansel flunks trialGlycoMimetics has been poleaxed by the news that its drug for a severe complication of sickle cell anaemia Share XGlycoMimetics craters as Pfizer says rivipansel flunks trialhttps://pharmaphorum.com/news/glycomimetics-craters-as-pfizer-says-rivipansel-flunks-trial/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
Pfizer confirms generic medicines merger with MylanPfizer and Mylan have announced an all-stock deal that would combine their off-patent medicines businesses, confirming speculation that Share XPfizer confirms generic medicines merger with Mylanhttps://pharmaphorum.com/news/pfizer-confirms-generic-medicines-merger-with-mylan/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
Array, Pierre Fabre bowel cancer therapy ‘could replace chemo’A new trial has shown for the first time that a combination of three targeted therapies can improve Share XArray, Pierre Fabre bowel cancer therapy ‘could replace chemo’https://pharmaphorum.com/news/array-pierre-fabre-bowel-cancer-therapy-could-replace-chemo/
NICE clears front-line NHS use for Pfizer’s lung cancer drug VizimproPfizer has stolen a march on rival AstraZeneca in the first-line non-small cell lung cancer category, after NICE Share XNICE clears front-line NHS use for Pfizer’s lung cancer drug Vizimprohttps://pharmaphorum.com/news/nice-clears-front-line-nhs-use-for-pfizers-lung-cancer-drug-vizimpro/
